Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of omarigliptin (MK-3102) vs sitagliptin added to metformin in type 2 diabetes
2013-000059-42Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omarigliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline in A1C. Started May 2013; status: completed.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-000059-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000059-42.